MEK抑制剂曲美替尼通过抑制ERK1/2和mTORC1信号改善肾纤维化
本研究在单侧输尿管梗阻(UUO)和腺嘌呤饮食两种小鼠肾纤维化模型及体外培养的人肾成纤维细胞中,探讨MEK抑制剂曲美替尼的抗纤维化作用。结果显示曲美替尼显著减轻胶原沉积和肌成纤维细胞分化与增殖,并抑制ERK1/2及下游mTORC1信号活化;在肌成纤维细胞活化后给药仍可改善纤维化进展。
要点
- 曲美替尼在UUO和腺嘌呤饮食小鼠模型中减轻胶原沉积和肌成纤维细胞分化。
- 曲美替尼抑制ERK1/2通路并下调mTORC1活化,减少α-SMA表达和成纤维细胞增殖。
- 肌成纤维细胞活化后给药仍改善肾纤维化进展,支持其治疗候选价值。
核心结论
- 曲美替尼在两种小鼠肾纤维化模型及人肾成纤维细胞中表现出抗纤维化效应,值得进一步研究作为慢性肾纤维化疾病的潜在治疗药物。
研究设计与样本
- 研究采用单侧输尿管梗阻(UUO)小鼠模型、腺嘌呤饮食喂养小鼠模型以及体外培养的原代人肾成纤维细胞。
- 研究使用免疫印迹分析、免疫组化染色等方法探讨抗纤维化作用的分子机制。
主要发现
- 曲美替尼显著减轻UUO和腺嘌呤喂养小鼠的胶原沉积及肌成纤维细胞分化和扩展。
- 在损伤肾脏中,曲美替尼抑制ERK1/2通路并改善mTORC1活化。
- 在TGF-β1刺激的原代人肾成纤维细胞中,曲美替尼抑制ERK1/2通路并抑制下游mTORC1活化。
- 曲美替尼降低肌成纤维细胞标志物α-平滑肌肌动蛋白表达并抑制肾成纤维细胞增殖。
- 在肌成纤维细胞活化后给药,曲美替尼仍显著改善肾纤维化进展。
临床怎么用
- 曲美替尼作为MEK抑制剂已用于黑色素瘤治疗,本研究提示其可能对慢性肾纤维化具有保护作用。
- 在肌成纤维细胞活化后给药仍有效,提示其可能用于纤维化已启动的肾脏疾病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: During kidney fibrosis, a hallmark and promoter of CKD (regardless of the underlying renal disorder leading to CKD), the extracellular-regulated kinase 1/2 (ERK1/2) pathway, is activated and has been implicated in the detrimental differentiation and expansion of kidney fibroblasts. An ERK1/2 pathway inhibitor, trametinib, is currently used in the treatment of melanoma, but its efficacy in the setting of CKD and renal fibrosis has not been explored. METHODS: We investigated whether trametinib has antifibrotic effects in two mouse models of renal fibrosis-mice subjected to unilateral ureteral obstruction (UUO) or fed an adenine-rich diet-as well as in cultured primary human fibroblasts. We also used immunoblot analysis, immunohistochemical staining, and other tools to study underlying molecular mechanisms for antifibrotic effects. RESULTS: Trametinib significantly attenuated collagen deposition and myofibroblast differentiation and expansion in UUO and adenine-fed mice. We also discovered that in injured kidneys, inhibition of the ERK1/2 pathway by trametinib ameliorated mammalian target of rapamycin complex 1 (mTORC1) activation, another key profibrotic signaling pathway. Trametinib also inhibited the ERK1/2 pathway in cultured primary human renal fibroblasts stimulated by application of TGF-β1, the major profibrotic cytokine, thereby suppressing downstream mTORC1 pathway activation. Additionally, trametinib reduced the expression of myofibroblast marker α-smooth muscle actin and the proliferation of renal fibroblasts, corroborating our in vivo data. Crucially, trametinib also significantly ameliorated renal fibrosis progression when administered to animals subsequent to myofibroblast activation. CONCLUSIONS: Further study of trametinib as a potential candidate for the treatment of chronic renal fibrotic diseases of diverse etiologies is warranted.
引用
- Andrikopoulos P, Kieswich J, Pacheco S, et al. The MEK Inhibitor Trametinib Ameliorates Kidney Fibrosis by Suppressing ERK1/2 and mTORC1 Signaling. J Am Soc Nephrol. 2018. PMID: 30530834. doi:10.1681/ASN.2018020209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。